Since its creation, B Cell Design has increased its expertise due to successful collaborations with scientific partners in therapeutic and diagnostic fields:
UMR CNRS 7276 - University of Limoges
This laboratory is directed by Pr. Michel COGNE and is B Cell Design’s historic partner. Its expertise ranges from the genetics of immune response, particularly focused on B lymphocyte biology. The laboratory has supported B Cell Design in its development and technological value creation.
B Cell Design is a the sole licensee for 3 patents emerging from this laboratory (co-applicant on one patent). A partnership is currently set up to study IgA nephropathies with the team of Jean-Claude Aldigier, Anne Druihle and Christelle Oblet.
INSERM 1110 - University of Strasbourg
Dr. Christiane MOOG
This team is studying innovative approaches to analyzing the first stages of viral infection, genome replication and the virus particle assembly in Hepatitis C, hepatitis B and HIV viruses.
B Cell Design worked with Dr Moog’s team on the development of the HIV vaccine candidate in a tripartite partnership with Sanofi-Pasteur. INSERM, Strasbourg University and B Cell Design are co-applicants for European patent no. 14305174.6 from 05/02/15.
McGill University, Montréal, Canada - Department of Microbiology and Immunology
Dr. Momar N'DAO
He sets up partnerships with laboratories such as CDC or NIH to study new methods for detecting parasites and to find new treatments and vaccines against parasites.
A preliminary study with B Cell Design is currently demonstrating the therapeutic interest of the IgA anti-C.Parvum. B Cell Design produced and characterized the IgAs and secretory IgAs used in this study. This collaboration is extended to other parasite diagnostic projects (calibrators, positive controls of diagnostic kits) and their therapeutic applications (toxoplasmosis, leishmaniosis ...)
UMR CNRS 7292 - University of François Rabelais - Tours
Pr. Yves Gruel, Dr Jérôme Rollin et au Pr Claire Pouplard - This team specializes in haemostasis and particularly in the study of heparin-induced thrombopenia (HIT). Rare but serious complications may occur following heparin treatments. This is mainly due to the induction of specific IgG anti-heparin/platelet factor 4 (FP4/H), triggering significant cell activation leading to thrombosis.
B Cell Design is working with Pr Gruel’s team on the development of a monoclonal human chimeric antibody directed against PF4/H, 5B9 mimicking a natural response.
IMP Laboratory - Claude Bernard University Lyon-1
This laboratory produces polymer materials and explores transverse fields by working on living science.
B Cell Design has joined a number of academic and private partners (see below) on the PecsDDeli project, funded by an ANR (National Research Agency) grant. It aims to develop smart colloids to deliver active principles through the mucous membrane, using monoclonal IgA1 antibodies as a vector to target HIV reservoir cells.
UMS 3760 - IBCP - Claude Bernard University Lyon-1
IBCP : Institut de Biologie et de Chimie des Protéines (biologie and proteins chemistry institute), LBTI Laboratoire de Biologie Tissulaire et d’Ingénierie Thérapeutique (tissue biology and therapeutic engineering laboratory) UMR 5305, CNRS/University of Lyon, University Lyon-1 – PECsDDeli project -
Dr Bernard Verrier.
This team is studying new concepts in therapeutic engineering.
For the PECsDDeli project, B cell Design and IBCP/LBTi are working to develop specific IgAs and sIgAs to deliver active principles against infectious agents through mucous membranes, using monoclonal IgA1 antibodies as a vector to target HIV reservoir cells.
GIMAP – Jean Monnet University- St Etienne
GIMAP: (Groupe d’Etude sur l’Immunité des Muqueuses et Agents Pathogènes, INSERM Centre d’Investigation Clinique en Vaccinologie, Universités de Lyon et de Saint-Etienne.) Mucosal immunity and pathogens study group, INSERM, Clinical investigation center for vaccines, Universities of Lyon and St Etienne.
Dr. Stéphane Paul.
This laboratory specializes in physiopathology and infectious diseases.
B Cell Design has developed an IgA1anti- HIV antibody to study mucosal immunity involved during infection as part of a collaboration (PECsDDeli, funded by an ANR grant) with teams led by Bernard Verrier, Thierry Delair, the CEA (ITMIT, Fontenay-Aux-Roses, Catherine Chapon) and Adjuvatis.